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Summary Cytarabine (ara-C) and gemcitabine (dFdC) are
commonly used anticancer drugs, which depend on the
equilibrative (ENT) and concentrative-nucleoside-
transporters to enter the cell. To bypass transport-related drug
resistance, lipophilic derivatives elacytarabine (CP-4055), ara-
C-5′elaidic-acid-ester, and CP-4126, (CO 1.01) gemcitabine-
5′elaidic-acid-ester, were investigated for the entry into the
cell, distribution, metabolism and retention. The leukemic
CEM-cell-line and its deoxycytidine-kinase deficient variant
(CEM/dCK-) were exposed for 30 and 60 min to the
radiolabeled drugs; followed by culture in drug-free medium
in order to determine drug retention in the cell. The cellular
fractions were analyzed with thin-layer-chromatography and
HPLC. Elacytarabine and CP-4126 were converted to the
parent compounds both inside and outside the cell (35–45%).
The ENT-inhibitor dipyridamole did not affect their uptake or
retention. Inside the cell Elacytarabine and CP-4126 predom-
inantly localized in the membrane and cytosolic fraction,
leading to a long retention after removal of the medium. In
contrast, in cells exposed to the parent drugs ara-C and dFdC,
intracellular drug concentration increased during exposure but
decreased to undetectable levels after drug removal. In the
dCK- cell line, no metabolism was observed. The concen-
trations of ara-CTP and dFdCTP reached a peak at the end of
the incubation with the drugs, and decreased after drug
removal; peak levels of dFdCTP were 35 times higher than
ara-CTP and was retained better. In contrast, after exposure to
elacytarabine or CP-4126, ara-CTP and dFdCTP levels
continued to increase not only during exposure but also
during 120 min after removal of the elacytarabine and CP-
4126. Levels of ara-CTP and dFdCTP were higher than after
exposure to the parent drugs. In conclusion, the lipophilic
derivatives elacytarabine and CP-4126 showed a nucleoside-
transporter independent uptake, with long retention of the
active nucleotides. These lipophilic nucleoside analogues are
new chemical entities suitable for novel clinical applications.
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transporter
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Introduction
The deoxynucleoside analogs ara-C and dFdC are drugs
commonly used in the treatment of a variety of cancers,
although ara-C is restricted for use in hematological
malignancies [1, 2], while dFdC is first line therapy for
non-small cell lung cancer, pancreatic cancer and bladder
cancer [3–5]. Due to their hydrophilic nature these drugs
are dependent on the equilibrative and concentrative
nucleoside transporters (hENT and hCNT) to cross the cell
membrane into the cell [6]. Both hENT and hCNT are
membrane transporters required for uptake of natural
nucleosides in the cell, and play an important role in the
uptake of nucleoside analogs. The subsequent rate-limiting
step in the activation of both drugs to its active triphosphate
form is the conversion to the intermediate monophosphate
by deoxycytidine kinase (dCK) [7, 8]. Both drugs can be
inactivated by deoxycytidine deaminase (CDA). The
secondary intermediate of dFdC, dFdC diphosphate
(dFdCDP), is known to inhibit ribonucleotide reductase,
which is essential in providing deoxyribonucleotides
required for DNA repair [9]. DNA polymerization is
stopped after incorporation of dFdC triphosphate (dFdCTP)
and one more nucleotide; this masked chain termination
prevents removal of dFdC by exonucleases [10]. Ara-C
triphosphate (ara-CTP) incorporation into DNA also causes
chain termination, while the active metabolite of ara-C can
inhibit DNA polymerase by competitive inhibition [1].
In order to enhance the uptake of the drugs into the cell
by making the drugs more lipophilic, various derivatives
containing a fatty acid side chain have been developed [11],
which are usually coupled to the 5′ position on the sugar
moiety or to the amino group of the base. The derivatives of
dFdC (CP-4126, now designated as CO 1.01) and ara-C
(CP-4055, elacytarabine) each contain a fatty acid at the 5′
position with a chain length of eighteen carbon atoms and
one trans-double bond (elaidic acid) in position 9. Elacy-
tarabine has shown remarkable antitumor activity in various
model systems including solid cancer xenografts in which
the parent drug ara-C has no activity [12, 13]. CP-4126 has
at least similar activity as dFdC in several xenografts
models, while it also has oral activity [14]. Other studies
[13, 16] have demonstrated that elacytarabine is still
dependent on activation by dCK, but that the drug has a
longer cellular retention and a different effect on DNA and
RNA synthesis compared to ara-C. In CP-4126 the fatty
acid chain also protected the dFdC from deamination [14],
but CP-4126 is also dependent on dCK for activation [14,
15]. Elacytarabine was investigated in a phase I clinical
study in solid tumors [17], showing a favorable and
predictable safety profile which was dose and schedule
dependent. Both drugs are currently in phase II studies.
Other lipophilic derivatives of predominantly ara-C have
shown at least similar accumulation of ara-CTP, and
sometimes a prolonged retention [18]. Since some of our
preliminary results indicated a delayed accumulation of the
active triphosphates as well as prolonged retention, the aim
of this study was to investigate uptake and metabolism of
Elacytarabine and CP-4126. For this proof-of-principle
study we used CEM cells and its dCK deficient variant to
discriminate between uptake and metabolism.
Materials and methods
Drugs
Elacytarabine and CP-4126 (now designated as CO-1.01)
were provided by Clavis Pharma (Oslo, Norway),
tetrahydrouridine (THU) was from Calbiochem (Merck,
Darmstadt, Germany), dipyridamole and ara-C were from
Sigma-Aldrich (St. Louis, MO, USA) and dFdC was
from Eli-Lilly (Indianapolis, IN, USA). The radioactively
labeled drugs were obtained from Moravek (Brea, CA,
USA); the drugs were labeled with tritium on the 5-C
site of the base. A mix of radioactive and non-
radioactive compounds was made for exposure of cells;
ara-C and elacytarabine were used at a concentration of
9.7 μM and a specific activity of 1789 and 1784 mCi/mmol
respectively, dFdC and CP-4126 were used at a final
concentration of 8.9 μM and a specific activity of 586 and
391 mCi/mmol, respectively.
Cell lines
For the experiments the CCRF-CEM human leukemia cell
line and its dCK negative variant (CEM/dCK-) were used.
CEM/dCK- cells are completely resistant to both ara-C and
dFdC and their prodrugs, due to the absence of dCK. IC50
values are given in Table 1. The latter cell line was
required to get a clean drug uptake and sequestration
pattern, not affected by activation of the parent drug. The
cell lines were cultured in RPMI medium (BioWhittaker,
Verviers, Belgium) supplemented with 10% fetal calf
serum (PAA laboratories, Pasching, Austria) and HEPES
buffer (BioWhittaker). Of the nucleoside influx trans-
porters, the CEM cell line only expresses hENT and not
hCNT [19]. Dipyridamole was used to inhibit the influx of
the drugs by hENT. In order to get a clean picture we also
added THU to inhibit deamination of ara-C and dFdC;
hence the only metabolic pathway available for the drugs
is activation by dCK.
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Drug uptake and metabolism
The method was based on a procedure described earlier
[20]. Shortly, cells were harvested and resuspended in fresh
medium at 5×106 cells/ml. Of this cell suspension 100 μl
was used for each experiment. To inhibit deamination by
CDA, THU was added at a final concentration of 100 μM
and was present during incubation and when incubated in
drug free medium, which is sufficient to keep deamination
inhibited [21]; the drugs were added to reach a final
concentration of 9.7 and 8.9 μM for ara-C/elacytarabine
and dFdC/CP-4126, respectively. The cells were incubated for
0, 30 and 60 min at 37°C. To measure intracellular drug
retention the drug containing medium was replaced after
60 min and the cells were incubated for 60 min in drug free
medium. Thereafter the cells were spun down (3000 g, 2 min,
4°C) and the medium was stored as extracellular fraction at
−20°C. The cells were washed with cold PBS (12000 g, 1 min,
4°C). The cell pellet was resuspended in 45 μl cold PBS and
nucleosides and nucleotides were extracted by addition of 5 μl
perchloric acid (5 M) and chilled on ice for 20 min. After
spinning down (12000 g, 3 min, 4°C) the perchloric acid pellet
containing the precipitated nucleic acids was resuspended in
200 μl NaOH (1 M). The supernatant containing the cytosolic
fraction was neutralized with 10 μl KH2PO4 (5 M) and stored
as intracellular fraction at −20°C. Using 3H-elacytarabine
and 3H-CP-4126 we did not find evidence that the prodrugs
were hydrolyzed to ara-C or dFdC under acidic conditions
used for precipitation of proteins and nucleic acids.
Of the extracellular and intracellular cytosolic samples 5 μl
was spotted on a plastic backed silica TLC plate (Merck
KgaA, Darmstadt, Germany) in order to separate ara-C from
elacytarabine and formed nucleotides and to separate dFdC
from CP-4126 and formed nucleotides. The chromatography
was performed with 3:2 chloroform/methanol as a mobile
phase. After separation the spots were visualized with UV
light and cut into separate scintillation vials, and radioactivity
was eluted by overnight incubation in methanol. The samples
were measured together with the perchloric acid pellet
samples in an LSC counter. All experiments were performed
in duplicate and repeated at least 3 times.
Intracellular localization
Intracellular localization of the lipophilic analogs was
investigated using a ProteoExtract™ Subcellular Proteome
Extraction Kit (Calbiochem). Cells were incubated with 9.7
and 8.9 μM of the radioactive drugs as described above and
deamination was inhibited by 100 μM THU. The samples
were incubated for 60 min at 37°C. After incubation the
cells were washed and with the different reagents provided
with the kit; the samples were separated into subcellular
fractions: a cytosolic, a membrane, a nuclear and a
cytoskeletal fraction. All experiments were performed in
duplicate and repeated at least 3 times. Differences were
evaluated using the Student’s t-test.
Triphosphate accumulation
Cells were treated with 1 and 10 μM of dFdC and ara-C,
respectively, while for the lipophilic analogs higher
concentrations of 10 and 100 μM was used, since initial
experiments demonstrated that this was required to achieve
similar triphosphate accumulation. The cells were incubated
for 60 min and retention of the triphosphates was
investigated after 60 and 120 min incubation in drug-free
medium. Dipyridamole was added to inhibit drug influx
and efflux by the hENT transporter. After incubation the
cells were spun down (12000 g, 1 min, 4°C) and the cell
pellet was resuspended in ice-cold PBS and incubated for
20 min at 4°C with 40% trichloroacetic acid to extract the
nucleotides. After centrifugation (10,000 g, 10 min, 4°C)
the supernatant was neutralized by addition of a 2-fold
excess of trioctylamine/1,1,2-trichlorotrifluorethane (1:4)
and spun down (10,000 g, 1 min) and the aqueous phase
containing the extracted nucleotides was stored at −20°C
until analysis by HPLC on a Whatman Partisphere SAX
column (GE healthcare, Chalfont St. Giles, UK) using
either isocratic (to separate ara-CTP from normal nucleo-
tides and quantifiy ara-CTP) or gradient (to separate
dFdCTP from other nucleotides and quantify dFdCTP)
elution as described earlier [22, 23].
Results
Incubation of the CEM and CEM/dCK- cell lines with
elacytarabine led to release of free ara-C in the extracellular
medium, which increased over time in both cell lines
(Fig. 1). After exposure of the CEM cell line to ara-C, the
levels of ara-C decreased gradually while the levels
remained the same in the CEM/dCK- cell line. Incubation
with elacytarabine followed by culturing in drug free
medium led to higher extracellular levels of ara-C than
after incubation with ara-C.
Table 1 Sensitivity of the wildtype CEM-CCRF cell line and its
deoxycytidine kinase deficient variant (CEM-dCK-) to ara-C,






Values are means (in μM) ± SEM of 4–8 separate experiments and were
determined after 72 h exposure to the drugs using the MTT assay [22].
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In contrast to elacytarabine, extracellular CP-4126 was
converted very rapidly to dFdC by both cell lines; after
30 min incubation almost all the extracellular CP-4126 was
converted to dFdC (Fig. 1). After incubation of the CEM
cell line with dFdC the levels decreased over time, although
this was not significant, while in the CEM/dCK- cell line
the levels remained the same. The dFdC formed from CP-
4126 showed the same trend as the normal dFdC levels,
some dFdC was left in the medium after removal of the
drugs. In contrast to data with elacytarabine, accumulation
of the dFdC after removal of the drug was limited.
After incubation with elacytarabine, intracellular ara-C
accumulated faster and to higher levels compared to
incubation with ara-C (Fig. 2). After removal of elacytar-
abine, ara-C continued to be released inside the cells. After
60 min incubation with elacytarabine, the extent of ara-C
accumulation was twice as high as after incubation with
ara-C. The absence of dCK did not affect the initial
accumulation of ara-C after incubation with elacytarabine,
but after 60 min less ara-C was present in the CEM/dCK-
cells than in the wild type CEM cell line. This difference is
most likely caused by the trapping of ara-C in nucleotides
in the CEM cells, but not in the CEM/dCK- cells (see
below). Intracellular dFdC formed from CP-4126 showed a
different accumulation profile as for dFdC itself (Fig. 2).
Levels of dFdC formed from CP-4126 were 10-times
higher compared to that after incubation with dFdC alone
and peaked after 30 min incubation, after which the levels
decreased and were comparable for dFdC from CP-4126
and from dFdC itself. Similarly, levels of dFdC from CP-
4126 were higher (6-times) than that from dFdC in the





























Fig. 1 Extracellular concentration of ara-C and dFdC after incubation
for 30 or 60 min (marked as 30 and 60) of the CEM or CEM/dCK- cell
lines with radioactive drugs. The concentrations of the prodrug and parent
drug were measured after 60 min exposure to the drugs and washing with
drug-free medium and culture for 60 min in drug free medium (marked at
60+60). a Ara-C after incubation with 9.7 μM [3H]-ara-C or [3H]-
elacytarabine (CP-4055), b dFdC after incubation with 8.9 μM [3H]-
dFdC or [3H]-CP-4126. Values represent means ± SEM of at least three
separate experiments. Ara-C levels in medium of CEM-dCK- cells were
significantly higher than in medium of CEM cells (P<0.01)
a
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Fig. 2 Intracellular accumulation of ara-C and dFdC after incubation
for 30 or 60 min of the CEM or CEM/dCK- cell line with radioactive
drugs (marked as 30 and 60). Retention of the prodrug and the parent
drug was measured after exposure for 60 min and washing with drug-
free medium and culture for 60 min in drug free medium (marked as
60+60). a Ara-C after incubation with 9.7 μM [3H]-ara-C or [3H]-
elacytarabine (CP-4055), b dFdC after incubation with 8.9 μM [3H]-
dFdC or [3H]-CP-4126. Values represent means ± SEM of at least
three separate experiments. Accumulation of ara-C from CP-4055
after 60 min and 60 min retention period was significantly higher in
CEM-cells than in CEM-dCK- cells, similarly accumulation of dFdC
from CP-4126 after 30 min was significantly higher in CEM
compared to CEM-dCK- cells (P<0.05)
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CEM/dCK-. However, dFdC levels were lower than in the
CEM cell line, possibly because of lack of metabolism in
the CEM/dCK- cells. No differences in accumulation after
removal of the drug between dFdC and dFdC formed from
CP-4126 were observed.
Exposure to radiolabelled ara-C led to some ara-C
accumulation in the nuclear pellet of CEM cells represent-
ing ara-C incorporation into DNA, but in the CEM/dCK-
cell line the accumulation of ara-C did not exceed the
background in line with the absence of dCK (Fig. 3).
However, after incubation with elacytarabine at least 100
times higher accumulation of radioactivity in the perchloric
acid pellet was observed than with ara-C. In contrast to
incubation with ara-C, the accumulation of radioactivity
after incubation with elacytarabine was similarly high in
CEM and CEM/dCK- cells and did not change over time.
Radioactivity in the pellet was retained at a similar level in
the pellet of CEM/dCK- and CEM cells, indicating that
this radioactivity most likely does not represent ara-C
incorporation into DNA. After incubation with 3H-dFdC
accumulation of radioactivity in the nuclear pellet,
representing 3-H-dFdC incorporation into DNA, showed
the same trend as for 3H-ara-C (Fig. 3). However,
radioactive CP-4126 showed a high accumulation in the
perchloric acid pellet of the CEM and CEM/dCK- cell
lines, which decreased over time. This decrease was more
rapid in CEM cells compared to CEM/dCK- cells, and
more rapid then for elacytarabine.
In order to verify that the difference in extracellular
concentration and intracellular accumulation of ara-C after
incubation with [3H]-elacytarabine or [3H]-ara-C was due to
hENT mediated transport for ara-C and not for elacytar-
abine, we added dipyridamole to the cell cultures. The
extracellular concentration of ara-C did not change in time
and was almost undetectable after washing the cells with
drug-free medium. Consequently no intracellular ara-C was
found after incubation with dipyridamole, also precluding
any passive diffusion of ara-C. However, dipyridamole did
not affect the accumulation of ara-C released from
elacytarabine, indicating that elacytarabine enters the cell
independently of the hENT transporter (Fig. 4), and that
ara-C is released from elacytarabine inside the cell. Similar
data were found for dFdC and CP-4126 (data not shown),
in which dipyridamole completely inhibited dFdC uptake,
excluding passive diffusion of dFdC, but did not affect
uptake of CP-4126 and subsequently release of dFdC.
Since the perchloric acid procedure not only precipitated
ara-C and dFdC incorporated into DNA, but also additional
elacytarabine and CP-4126, this precluded measurement of
ara-C and dFdC incorporation into DNA after exposure to
elacytarabine or CP-4126. In order to get more insight in
the formation of active metabolites formed from the
prodrugs we therefore determined the accumulation of
triphosphates (ara-CTP and dFdCTP). After 60 min incu-
bation with ara-C or dFdC, more triphosphates were formed




































































































Fig. 3 Nuclear accumulation
and retention of radiolabeled
ara-C (a), elacytarabine (CP-
4055) (b), dFdC (c) and CP-
4126 (d). The nuclear pellets of
CEM and CEM/dCK- cells were
analyzed for radiolabeled
metabolites after incubation for
30 or 60 min (marked as 30 and
60) with 9.7 μM [3H]-ara-C (a)
or [3H]-elacytarabine (CP-4055)
(b), 8.9 μM [3H]-dFdC (c) or
[3H]-CP-4126 (d). Retention
was studied after 60 min expo-
sure followed by washing the
cells and resuspension in drug-
free medium for 60 min (marked
as 60+60). Values represent
means ± SEM of at least three
separate experiments. Accumu-
lation of radiolabeled CP-4126
was significantly lower than that
of CP-4055 (P<0.01)
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respectively (Fig. 5). The concentrations of ara-CTP and
dFdCTP formed from ara-C or dFdC decreased after
washing away the drugs but the concentration of ara-CTP
from elacytarabine continued to increase while dFdCTP
from CP-4126 was retained at a similar level. In order to
completely block carrier-mediated transport we added the
ENT inhibitor dipyridamole to the assay. CEM cells do not
express CNTs which may also transport dFdC. Dipyridamole
completely inhibited entry of the parent compounds, abolish-
ing accumulation of ara-CTP and dFdCTP. However, dipyr-
idamole even increased the concentration of triphosphates
from the prodrugs even after washing away the drugs. Earlier
we demonstrated that CEM/CK- cells do not phosphorylate
deoxycytidine analogs because of the dCK deficiency [24].
Neither ara-C or Elacytarabine were phosphorylated to
detectable levels in the CEM/dCK- cells [24], since Ara-C
can only be phosphorylated by dCK. Although alternative
kinases such as thymidine kinase 2 can phosphorylate dFdC,
but we could not detect any dFdCTP in the CEM/dCK- cells.
Even using a more sensitive LC-MS-MS assay for all dFdC-
phosphates [25], did not give evidence for formation of any
dFdC nucleotide in the CEM/dCK- cells, while dFdC-
phosphates were easily detectable in wild-type cells.
Because of the unexpected high accumulation of
radioactivity in the perchloric acid pellet of both CEM
and CEM/dCK- cells, we assumed an accumulation of the
lipophilic analogs in subcellular fractions, either protein-
bound or in lipid vesicles, which were precipitated by
perchloric acid. Since this might also explain the longer
retention of the lipophilic analog in the cell, we investigated
the subcellular distribution of the drugs (Fig. 6). The more
elaborate procedure enabled to analyze accumulation in


























CP-4055 Ara-C from CP-4055 Ara-C
Fig. 4 Effect of dipyridamole on (a) Extracellular concentration and
(b) intracellular accumulation of ara-C and elacytarabine (CP-4055) in
CEM cells (marked as 30 and 60). Cells were incubated for 30 and
60 min with 9.7 μM [3H]-ara-C or [3H]-elacytarabine (CP-4055), after
which elacytarabine and ara-C were measured. Concentrations of the
prodrug and parent drug were measured after 60 min exposure and
washing the cells with drug free medium and incubation for 60 min in
drug free medium (marked as 60+60). Values represent means ± SEM








































Fig. 5 Ara-CTP (a) and dFdCTP (b) accumulation in the CEM cell
line after 60 min incubation with 10 μM ara-C, 100 μM elacytarabine
(CP-4055), 1 μM dFdC or 10 μM CP-4126 with and without
inhibition of hENT by dipyridamole. Intracellular concentrations of
the triphosphates were measured after 60 min exposure and washing
the cells with drug-free medium and subsequent culture for 60 and
120 min in drug-free medium (marked as 60+60 and 60+120). Values
represent means ± SEM of at least three separate experiments.
Accumulation (60 min) of ara-CTP and dFdCTP was not different
when comparing ara-C incubation with elacytarabine or dFdC with
CP-4126. However, the retention (60+120) of ara-CTP and of
dFdCTP was significantly higher in cells incubated with elacytarabine
(p<0.01) or CP-4126 (p<0.05), respectively, compared to incubation
with ara-C or dFdC, as well as the effect of dipyridamole on dFdCTP
retention (P<0.01) of ara-CTP retention (P<0.05)
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different cellular compartments. In the parent CEM cell line
both the lipophilic analogs and the nucleoside analogs
accumulated predominantly in the cytosolic fraction, while
a considerable amount of elacytarabine was found in the
membrane fraction. However, in the CEM/dCK- cell line
the relative accumulation of the lipophilic analogs in the
membrane fraction was much higher, as well as in the
nucleus, possibly because of a lack of metabolism in these
cells. This fits very well with the high accumulation of the
labeled Elacytarabine and CP-4126 in the nuclear fraction
as found with perchloric acid precipitation
Discussion
The lipophilic analogs CP-4126 (gemcitabine–5′-elaidic
acid ester) and elacytarabine (cytarabine–5′-elaidic acid
ester) showed differential effects in metabolism and
accumulation not only compared to their respective parent
compounds but also compared to each other. The prodrugs
seem to be trapped in an intracellular compartment,
subsequently releasing the prodrug itself or the parent
compound. Both analogs were converted by a non-
identified esterase to their parent compounds outside but
predominantly inside the cell.
In the medium CP-4126 disappeared very rapidly and
was converted to dFdC but accumulation in cells of both
dFdC and partly dFdCTP was higher than for dFdC itself.
The difference in conversion rate between elacytarabine
and CP-4126 is probably caused by the fluorine atoms in
the sugar of the dFdC part of the analog (Table 2). The
longer bond length for CP-4126 between the C and O
atoms indicates a weaker binding, which might explain the
more rapid hydrolysis of CP-4126 to dFdC relative to
elacytarabine hydrolysis to ara-C [26]. Although this does
not seem to affect the in vivo efficiency of the drug it does
cause the compound to be converted rapidly in the
experimental setup of our experiments.
The most pronounced difference between prodrug and
parent compound was observed for elacytarabine and ara-C.
Ara-C itself was not retained for a long period, similar to
other studies with ara-C in leukemic cell lines and patient
samples [27, 28]. However, when cells were exposed to

































































































































Fig. 6 Subcellular localization
of radioactivity from 9.7 μM
Elacytarabine (CP-4055) (a,b)
and ara-C (a,b), or 8.9 μM CP-
4126 (c,d) and dFdC (c,d) in the
CEM (a,c) and CEM/dCK-
(b,d) cell lines. Relative
amounts after 60 min incubation
with the radioactive drugs; total
activity was calculated by set-
ting the sum of radioactivity in
all fractions at 100%, and sub-
sequently calculating the per-
centage in each fraction.
Accumulation of elacytarabine
label and CP-4126 label was
significantly higher in the mem-
brane fraction compared to
accumulation of ara-C (p<0.05)
or dFdC (p<0.02) label,
respectively
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incubation in drug-free medium. This was also reflected in
ara-CTP accumulation, which after incubation with elacy-
tarabine continued to increase when elacytarabine was
washed away, in contrast to ara-CTP from ara-C, which
decreased rapidly during incubation in drug-free medium
[22]. Elacytarabine was shown to enter the cell indepen-
dently of the hENT transporter, thereby circumventing a
possible resistance mechanism to ara-C, confirming previ-
ous results [12, 29]. Inhibition of the hENT transporter
caused an increased accumulation of both ara-CTP and
dFdCTP from the lipophilic analogs. The reason for this
effect might be the specific inhibition of hENT, which also
catalyzes efflux of ara-C and dFdC, which accumulated in
the cell after being released from the prodrugs. Since CEM
cells do not express CNTs, under these conditions only
diffusion may play a role in influx and efflux of nucleo-
sides, but nucleotides are too polar to diffuse out of the
cells. Although BCRP and MRP-4 may also be inhibited by
dipyridamole, the inhibition of hENT seemed to be the most
prominent effect, since no uptake of ara-C or dFdC was
observed. An inhibitory effect of dipyridamole on efflux of
the mononucleotides of elacytarabine and CP-4126 may
theoretically be part of the explanation as well.
Also dFdC released from CP-4126 rapidly reached
higher concentrations of dFdC than when cells were
incubated with dFdC. Subsequently this increase in dFdC
from CP-4126 led to a high accumulation of dFdCTP. In
contrast to ara-CTP, dFdCTP elimination after dFdC
exposure is biphasic and much slower [9, 23]. The retention
of dFdCTP from CP-4126 even seemed to be longer. The
higher sensitivity of the CEM wild type cells to dFdC and
CP-4126 compared to ara-C and Elacytarabine is reflected
in the higher accumulation of dFdCTP compared to ara-
CTP. Unfortunately, the prodrugs were not able to bypass
resistance to ara-C and dFdC in CEM/dCK- cells. Both
Elacytarabine and CP-4126 do not contain a phosphate
between the sugar and elaidic acid (Table 2); therefore they
can only be broken down to the nucleoside analogs ara-C
and dFdC and elaidic acid. Despite the higher accumulation of
dFdC in CEM/dCK- cells, these cells can not phosphorylate
ara-C or dFdC, which is due to the deficiency of dCK.
Although dFdC is also a substrate for other kinases such as
thymidine kinase 2 [7], their activity is apparently too low in
these cells to catalyze the formation of detectable levels of
dFdC nucleotides.
The differences between lipophilic analogs and parent
compounds can at least partly be explained by the
intracellular localization of the compounds. The lipophilic
fatty acid chain attached to the drug caused the drug to be
retained in a membrane fraction inside the cell. This
accumulation, possibly in a membrane vesicle, caused a
slower and prolonged release of the nucleoside analog from
the lipophilic analogs. This ultimately caused an effect that
is different from the nucleoside analogs from which the
lipophilic analogs are derived. This differential effect of the
lipophilic analogs compared to the parent compounds
shows that these prodrugs have a different mechanistic
effect in cells [11]. The intracellular sequestration of the
lipophilic prodrugs in the cell may have profound implica-
tions for the clinical application of these drugs. This
prolonged intracellular accumulation of the prodrugs and
their metabolites will lead to a different drug behavior
compared to ara-C and dFdC themselves. The antitumor
activity of both ara-C and dFdC is dependent on the
duration of retention of the active metabolite. Therefore the
longer retention of the prodrug and of the triphosphates
represents a favorable property compared to the parent drug
and offers promise to improve treatment of malignancies
currently being treated with ara-C or dFdC, and to treat
other malignancies with these drugs. Since accumulation of
ara-CTP has been shown to be a valuable pharmacody-
namic biomarker for the efficacy of ara-C in leukemia,
these levels should be monitored in clinical studies with
Elacytarabine, while those of dFdCTP should be measured
in studies with CP-4126.
Both the independence on influx transporters and the
continuing accumulation and retention after removal of the
drugs, create the possibility for novel combinations and
treatment in tumors where the parent compounds show less
or no effect.



























 CP-4055 CP-4126 
Bond Bond length, Å Bond length, Å 
C-5’ – O-5’ 1.4049 1.4309 
C-1’’ – O-5’ 1.3600 1.4285 
C=O 1.21 1.22 
The C-O bonds (C-5′-O-5′and C-1″-O-5′) were calculated using
ChemBioDraw ultra 11.0 [26].
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